The Dementia and Movement Disorder Treatment Market is being driven by Growing geriatric population
The Dementia and Movement Disorder Treatment Market is expected to grow at a CAGR of 7.28% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 8.55 billion. The global market for dementia and movement disorder treatments is predominantly driven by MAO inhibitors, AChE inhibitors, and glutamate inhibitors. These drugs are utilized for managing various forms of dementia, including Lewy body dementia, and movement disorders, such as Parkinson's disease. The shared pathological conditions of these diseases, characterized by cognitive impairment due to neurofibrillary tangles and amyloid plaques, as well as the presence of Lewy bodies in both Lewy body dementia and Parkinson's disease, complicate diagnosis and treatment approaches.
Get more information on Dementia and Movement Disorder Treatment Market by requesting a sample report
The market is segmented based on
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
Market Scope |
|
Report Coverage |
Details |
Page number |
177 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.28% |
Market growth 2024-2028 |
USD 8.55 billion |
Market structure |
market_structure.ucfirst |
YoY growth 2023-2024(%) |
6.63 |
Key countries |
US, Canada, Germany, UK, France, India, Japan, China, South Korea, UAE, Brazil, US, Canada, Germany, UK, and France |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
The Dementia and Movement Disorder Treatment Market encompasses various interventions for neurological disorders, focusing on neurological rehabilitation to address cognitive decline and motor control issues, including gait disturbances and falls prevention. Medication adherence, lifestyle modifications, exercise therapy, diet and nutrition, cognitive enhancement, brain stimulation, and virtual reality therapy are among the approaches. Assistive technology, adaptive equipment, home modifications, caregiver training, support groups, community resources, end-of-life care, ethical considerations, patient advocacy, and healthcare policy are essential components of comprehensive care. Clinical trials design, data collection, clinical outcomes assessment, cost-effectiveness analysis, health economics, value-based care, precision neurology, digital health, remote patient monitoring, big data analytics, and biomedical engineering are crucial for advancing research and improving treatment outcomes.
The global dementia and movement disorder treatment market is a significant segment within the larger pharmaceuticals market, which is a key component of the overall healthcare industry. According to Technavio, the pharmaceuticals market, encompassing entities involved in R&D or manufacturing of generic and non-generic drugs, veterinary drugs, and biotechnology products, was valued at USD1,495.51 billion in 2023. Factors driving the growth of this market include the increasing global population aging, leading to a larger demographic susceptible to neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's. This demographic shift is expected to significantly boost the demand for treatments addressing cognitive impairment and motor dysfunction.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted